John Lee
2021 - PhaseBio Pharmaceuticals
In 2021, John Lee earned a total compensation of $856.3K as Chief Medical Officer at PhaseBio Pharmaceuticals, a 6% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $192,003 |
|---|---|
| Option Awards | $207,414 |
| Salary | $442,900 |
| Other | $13,981 |
| Total | $856,299 |
Lee received $442.9K in salary, accounting for 52% of the total pay in 2021.
Lee also received $192K in non-equity incentive plan, $207.4K in option awards and $14K in other compensation.
Rankings
In 2021, John Lee's compensation ranked 9,277th out of 12,415 executives tracked by ExecPay. In other words, Lee earned more than 25.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,277 out of 12,415 | 25th |
Division Manufacturing | 4,113 out of 5,508 | 25th |
Major group Chemicals And Allied Products | 1,813 out of 2,378 | 24th |
Industry group Drugs | 1,610 out of 2,099 | 23rd |
Industry Pharmaceutical Preparations | 1,194 out of 1,549 | 23rd |
Source: SEC filing on April 22, 2022.
Lee's colleagues
We found two more compensation records of executives who worked with John Lee at PhaseBio Pharmaceuticals in 2021.
News
Marathon Patent Group CFO Hugh Gallagher receives $4.8M in 2022
June 23, 2023
Decibel Therapeutics CEO Laurence Reid's 2022 pay jumps 54% to $1.2M
April 28, 2023
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2021 pay slips 13% to $1.5M
April 22, 2022
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2019 pay jumps 102% to $1.2M
April 24, 2020
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2018 pay jumps 37% to $596K
April 5, 2019